- $182.21bn
- $227.49bn
- $36.75bn
Focus: Drugmakers delay some European launches with a wary eye on Trump's pricing policies
US FDA warns of liver injury cases tied to Amgen's rare disease drug (updated)
US FDA warns of liver injury cases tied to Amgen's rare disease drug
Focus: Drugmakers delay some European launches with a wary eye on Trump's pricing policies
Brief: Amgen's Repatha Cuts Risk Of First Major Cardiovascular Event By 31% In High-Risk Patients
Takeda's psoriasis pill succeeds in late-stage studies
Brief: EMA's CHMP Recommends Extension Of Therapeutic Indication For Pfizer's Hympavzi
GSK and Amgen to add medicines to TrumpRx, Fox Business reports
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Brief: Amgen Announces 2026 Second Quarter Dividend
Kyowa Kirin stops development of skin condition treatment (updated)
Generate Biomedicines shares fall 6% in weak Nasdaq debut for drug developer (updated)
Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Brief: Amgen Inc Files For Four-Part Senior Notes Offering Of Up To $4 Bln
Brief: European Commission Approves Amgen's Uplizna® For Generalized Myasthenia Gravis
CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists
Live Markets: Nasdaq, S&P 500 fall on more tech weakness, Amgen buoys Dow
U.S. STOCKS ON THE MOVEx-IDEX Corp, Union Pacific, Qualcomm